U.S. Semiconductors Stock News

NasdaqGS:TROW
NasdaqGS:TROWCapital Markets

T. Rowe Price Group (TROW) Margin Slippage Reinforces Earnings Pressure Narrative

T. Rowe Price Group (TROW) just wrapped up FY 2025 with fourth quarter revenue of US$1.9 billion and basic EPS of US$1.99, alongside net income of US$434.2 million, as the asset manager continued to translate its fee base into solid earnings. Over the past few quarters, revenue has moved from US$1.72 billion in Q2 2025 to US$1.89 billion in Q3 and US$1.93 billion in Q4, while basic EPS shifted from US$2.24 to US$2.88 and then US$1.99. This sets up a mixed but still profitable backdrop for the...
NasdaqGS:VTRS
NasdaqGS:VTRSPharmaceuticals

Is It Time To Reassess Viatris (VTRS) After Its Recent Share Price Strength

If you are wondering whether Viatris shares still offer value at around US$14.36, you are not alone; many investors are asking the same question right now. The stock has posted returns of 10.7% over 7 days, 16.1% over 30 days, 15.2% year to date, 37.8% over 1 year, 38.2% over 3 years and a 4.5% decline over 5 years, which has drawn attention to how the market is currently pricing the business. Recent news flow around Viatris has focused on its positioning within the pharmaceuticals and...
NasdaqGS:PFG
NasdaqGS:PFGInsurance

Is Principal Financial Group (PFG) Pricing Look Attractive After Strong Five-Year Share Performance

If you are wondering whether Principal Financial Group's recent share price reflects fair value or leaves some room on the table, this breakdown is designed to help you size that up quickly. The stock closed at US$96.40 recently, with returns of 2.5% over 7 days, 6.5% over 30 days, 7.8% year to date, 24.3% over 1 year, 17.9% over 3 years and 113.0% over 5 years, which may shape how investors think about both opportunity and risk today. Recent headlines around Principal Financial Group have...
NYSE:CTVA
NYSE:CTVAChemicals

Corteva (CTVA) Margin Improvement Reinforces Bullish Earnings Narrative Despite Slower Revenue Growth

Corteva (CTVA) has wrapped up FY 2025 with Q4 revenue of US$3.9b and a basic EPS loss of US$0.80, while the trailing twelve month line shows revenue of US$17.4b and basic EPS of US$1.75, alongside earnings growth of 40.2% over the last year. Over recent periods, revenue has sat in a US$2.6b to US$6.5b quarterly range with EPS swinging between quarterly profits and losses, while on a trailing basis earnings are forecast to grow about 20.7% per year. With a trailing net margin of 6.9% versus 5%...
NasdaqGS:DSGR
NasdaqGS:DSGRTrade Distributors

Is It Time To Reassess Distribution Solutions Group (DSGR) After Mixed Share Price Performance?

If you are wondering whether Distribution Solutions Group at around US$29.67 offers good value today, you are not alone. This article is here to break that question down in plain terms. The share price has moved 5.9% over the last week and 1.6% over the last month, while the year to date return sits at 5.8% and the 1 year return at a 6.3% decline, with a 30.2% gain over 3 years providing longer term context. Recent company updates and corporate developments have kept Distribution Solutions...
NasdaqGS:INNV
NasdaqGS:INNVHealthcare

InnovAge Holding (INNV) Profitability Return Challenges Bear Narratives On Sustainability

InnovAge Holding (INNV) has reported Q2 2026 results with revenue of US$239.7 million and basic EPS of US$0.08, alongside net income of US$10.6 million. Its trailing 12 month figures show revenue of US$915.4 million and basic EPS of US$0.05 on net income of US$6.5 million. The company’s quarterly revenue moved from US$209.0 million in Q2 2025 to US$239.7 million in Q2 2026, with basic EPS shifting from a loss of US$0.10 per share to a profit of US$0.08. This places improving margins and the...
NYSE:DVA
NYSE:DVAHealthcare

DaVita (DVA) Margin Compression To 5.3% Challenges Bullish Valuation Narratives

DaVita (DVA) has just wrapped up FY 2025 with Q4 revenue of US$3.6b and basic EPS of US$3.00, supported by Q4 net income from continuing operations of about US$209 million and an additional US$25 million from discontinued operations. Over the past six quarters, the company has seen quarterly revenue move from US$3.3b in Q4 2024 to US$3.6b in Q4 2025, while basic EPS across that period ranged between roughly US$2.05 and US$3.18. This sets up a set of results where the key question for...
NasdaqGS:AZTA
NasdaqGS:AZTALife Sciences

Azenta (AZTA) Returns To Quarterly EPS Loss Challenging Recent Profitability Narrative

Azenta (AZTA) opened its Q1 2026 update with revenue of $148.6 million and a basic EPS loss of $0.11, setting a measured tone for the quarter. The company has seen quarterly revenue move within a relatively tight band, from $151.1 million in Q4 2024 to $147.5 million in Q1 2025, $143.4 million in Q2 2025, $143.9 million in Q3 2025, $159.0 million in Q4 2025 and now $148.6 million in Q1 2026. EPS swung from a small loss of $0.02 in Q4 2024 to a profit of $1.12 in Q4 2025 before returning to a...
NasdaqGS:CDW
NasdaqGS:CDWElectronic

CDW (CDW) Net Margin Compression Tests Bullish Narratives After Q3 FY 2025 Results

CDW (CDW) has put fresh numbers on the table for FY 2025, with third quarter revenue of US$5.7b, basic EPS of US$2.22 and net income of US$291m, giving investors a clearer read on how the year is shaping up. The company has seen revenue move from US$5.2b in Q4 2024 to US$5.2b in Q1 2025, US$6.0b in Q2 2025 and US$5.7b in Q3 2025. Over the same period, quarterly EPS went from US$1.98 to US$1.70, US$2.06 and US$2.22, setting the scene for investors to focus on how these results tie back to...
NYSE:THG
NYSE:THGInsurance

Hanover Insurance Group (THG) Combined Ratio Improvement Challenges Bearish Profitability Narratives

Hanover Insurance Group (THG) has released its FY 2025 numbers with fourth quarter revenue of US$1,671.8 million and basic EPS of US$5.52, capped off by trailing twelve month revenue of US$6.6 billion and EPS of US$18.51. Over recent reporting periods the company has seen revenue move from US$1,584.3 million and EPS of US$4.65 in Q4 2024 to US$1,671.8 million and EPS of US$5.52 in Q4 2025. Trailing net income reached US$660.7 million and margins sat at 10% over the last year, giving investors...
NasdaqGS:CTSH
NasdaqGS:CTSHIT

Cognizant (CTSH) Margin Decline To 10.2% Revives Bearish Profitability Narratives

Cognizant Technology Solutions (CTSH) opened FY 2025 with Q1 revenue of US$5.1b and basic EPS of US$1.34, followed by Q2 revenue of US$5.2b and EPS of US$1.31, and then Q3 revenue of US$5.4b with EPS of US$0.56, setting a clear view of how the top and bottom line have tracked through the year. Over the past few quarters, revenue has moved from US$4.9b in Q2 2024 to US$5.1b in Q4 2024 and then to US$5.1b, US$5.2b and US$5.4b in Q1, Q2 and Q3 2025 respectively. Basic EPS shifted from US$1.14...
NasdaqGM:FCEL
NasdaqGM:FCELElectrical

FuelCell Energy (FCEL) Valuation Check After Executive Departure And Severance Disclosure

FuelCell Energy (FCEL) has drawn fresh attention after disclosing that its employment relationship with former Executive Vice President, General Counsel and Corporate Secretary Joshua Dolger ended on January 6, 2026, under a detailed separation agreement. See our latest analysis for FuelCell Energy. At a share price of US$7.72, FuelCell Energy has seen a 5.03% 1 day share price gain, but the 7 day and 90 day share price returns of 19.50% and 9.07% declines suggest momentum has been fading,...
NYSE:TDG
NYSE:TDGAerospace & Defense

TransDigm Group (TDG) Net Margin At 21.1% Reinforces Bullish Profitability Narratives

TransDigm Group (TDG) opened fiscal 2026 with Q1 revenue of US$2.3b and basic EPS of US$6.63, alongside net income of US$386m. This sets a clear reference point against a trailing twelve month EPS of US$31.08 on revenue of US$9.1b and net income of US$1.8b. The company has seen quarterly revenue move from US$2.0b and EPS of US$7.62 in Q1 2025 to US$2.3b and EPS of US$6.63 in Q1 2026. Over the same period, trailing twelve month revenue has shifted from US$8.2b with EPS of US$28.37 to US$9.1b...
NYSE:AMP
NYSE:AMPCapital Markets

Is It Time To Reassess Ameriprise Financial (AMP) After Strong Multi‑Year Share Price Gains

If you are wondering whether Ameriprise Financial's current share price gives you genuine value, this article will help you size up what you might actually be paying for. The stock last closed at US$530.05, with returns of 6.4% over the past week, 7.3% over the last month, 7.3% year to date and 0.3% over the past year, set against longer term returns of 56.5% over three years and 166.6% over five years. Recent coverage around Ameriprise Financial has focused on its position as a large,...
NYSE:MRK
NYSE:MRKPharmaceuticals

Merck (MRK) Margin Surge And 56.7% Earnings Growth Challenge Cautious Growth Narratives

Merck (MRK) has put up another solid quarter for FY 2025, with Q3 revenue of US$17.3b and basic EPS of US$2.32 alongside net income of US$5.8b. The company has seen revenue move from US$16.7b in Q3 2024 to US$17.3b in Q3 2025, while trailing twelve month EPS sits at US$7.57 and net income at US$19.0b. This gives investors a clear read on a business that is pairing sizeable sales with a thick profit margin. See our full analysis for Merck. With the latest numbers on the table, the next step is...
NYSE:OLN
NYSE:OLNChemicals

Olin’s Soft Quarter And Chlorine Headwinds Versus Valuation Opportunity

Olin Corporation (NYSE:OLN) reported weaker than expected fourth quarter results, with performance pressured by operational issues and supply constraints. The company cited reduced demand for chlorine as a key headwind affecting its chemicals business in the period. In response, Olin is pursuing cost reductions, entering a long term supply agreement, and planning an expansion project in Brazil to support future sales. Olin is a major chlor-alkali and epoxy producer, as well as a significant...
NasdaqGS:AUGO
NasdaqGS:AUGOMetals and Mining

Aura Minerals Record 2025 Output Raises Questions On Valuation And Cash Flows

Aura Minerals reported record high Q4 and full-year 2025 production across its six operating mines. Q4 2025 output was higher year over year and above the company’s public production guidance. The update is material for shareholders of NasdaqGS:AUGO and has not yet been widely discussed on this platform. Aura Minerals, traded as NasdaqGS:AUGO, is coming off a very strong operational year, capped by record Q4 and full-year 2025 production. The shares last closed at $64.72 after a 29.4% gain...
NYSE:AAP
NYSE:AAPSpecialty Retail

Advance Auto Parts Resets With New Rewards Program And Store Overhaul

Advance Auto Parts (NYSE:AAP) has launched a new tiered loyalty program, Advance Rewards, replacing its Speed Perks offering. The company is rolling out an extensive restructuring effort that includes closing more than 700 stores and opening larger market hub locations. These moves are part of a broader push under CEO Shane O'Kelly to reshape operations and customer engagement. Advance Auto Parts enters this reset with shares at $50.70 and a mixed performance profile. The stock is up 30.4%...
NasdaqGS:ARCB
NasdaqGS:ARCBTransportation

Is ArcBest’s (ARCB) Profit Squeeze Reshaping Its Capital Allocation And Leadership Strategy?

In late January 2026, ArcBest reported Q4 2025 results showing sales of US$972.69 million and a net loss of US$8.12 million, alongside full-year revenue of US$4.01 billion and significantly lower net income than the prior year. While earnings missed analyst expectations and margins came under pressure from soft freight rates, ArcBest continued to invest in efficiency, expanded its board with new finance and technology expertise, and completed a long-running share repurchase program. Against...
NYSE:OTIS
NYSE:OTISMachinery

Is It Time To Reassess Otis Worldwide (OTIS) After Recent Share Price Weakness

If you are wondering whether Otis Worldwide's current share price lines up with its underlying value, this article will walk through the key numbers so you can judge that for yourself. Otis Worldwide's shares recently closed at US$87.16, with a 3.7% decline over 7 days, 1.3% decline over 30 days, 1.3% decline year to date and 6.0% decline over 1 year, set against gains of 9.5% over 3 years and 46.0% over 5 years. Recent news coverage around Otis Worldwide has focused on its position as a...
NasdaqGS:TER
NasdaqGS:TERSemiconductor

Teradyne (TER) Margin Decline To 17.4% Tests Bullish High Quality Earnings Narrative

Teradyne’s FY 2025 Earnings Snapshot Teradyne (TER) has wrapped up FY 2025 with fourth quarter revenue of US$1.1 billion and basic EPS of US$1.64, setting the tone for how investors assess the latest move in profitability. The company has seen quarterly revenue move from US$752.9 million in Q4 2024 to US$1.1 billion in Q4 2025, while basic EPS shifted from US$0.90 to US$1.64 over the same period, providing a clear view of how the top and bottom line have tracked together. With a trailing 12...
NYSE:DLB
NYSE:DLBSoftware

How Dolby’s Q1 Beat, Higher Guidance, and Expanding Licensing Will Impact Dolby Laboratories (DLB) Investors

In late January 2026, Dolby Laboratories reported first‑quarter revenue of US$346.71 million and net income of US$53.33 million, with earnings per share lower than a year earlier but ahead of analyst expectations, while affirming a US$0.36 dividend and issuing higher full‑year guidance. Beyond the headline numbers, Dolby underscored growing traction for Dolby Atmos, Dolby Vision 2, and new imaging initiatives such as Dolby OptiView and automotive partnerships, which together expand its...
NasdaqGS:ARWR
NasdaqGS:ARWRBiotechs

Is Arrowhead Pharmaceuticals (ARWR) Pricing Reflect Recent RNAi Progress And Strong Share Price Gains?

If you are looking at Arrowhead Pharmaceuticals and wondering whether the recent excitement matches the stock's underlying value, this article will walk you through the key signals to watch. The share price sits at US$72.14 after returns of 7.8% over the past week, 6.4% over the past month, 6.4% year to date, 266.6% over the past year and 114.6% over three years, while the five year return is negative at 19.7%. Recent coverage around Arrowhead has focused on its progress in RNA interference...